“My ultimate goal is to cure cancer”
Norbert Kraut, our Global Head of Cancer Research, shares how we are advancing science to bring new treatment options for people living with cancer.
Search
Spesolimab Phase II data
New data published in NEJM shows spesolimab improved signs & symptoms of GPP flares
Social Media Data Privacy and Cookies Statement
Family owned
Did you know that Boehringer is still family-owned? Read this article to learn more about our culture. Check out our Careers Page for more talent insights!
The Research Process
The Research Process
Sustainable medicines that help minimize environmental impact
How we collaborate with renowned experts to lead the way in reducing solvent waste, as part of our efforts to embed sustainability into our core business.
Liu
Hear Liu share his experience of being diagnosed with type 2 diabetes and heart disease on the same day and the impact this simultaneous diagnosis has had on his life as he knew it.
Why is Diversity, Equity and Inclusion important to us?
Why is Diversity, Equity and Inclusion important to us?
Elke
People with Type 2 diabetes (T2D) have an increased risk of heart disease.
Isabel
In this video, Isabel shares how watching her children and grandchildren grow up inspires her to take the necessary steps to manage her life with type 2 diabetes and heart disease.
Reinhold
People with type 2 diabetes have an increased risk of heart disease and this can have a profound impact on their everyday lives
Retinal Diseases
Retinal Diseases
Mental Health
Mental Health
Four Pillars Cancer Immunology
Boehringer Ingelheim is focusing cancer immunology research on T cell engagers, cancer vaccines, oncolytic viruses and immune & stromal modulation
Exploring innovation in interstitial lung disease (ILD)
Interstitial lung disease (ILD) describes a group of over 200 lung disorders characterized by inflammation and scarring of the interstitium of the lungs.
Patient documentary - From diagnosis to everyday living
10 things you should know about rabies
10 things you should know about rabies
What are lay summaries
Boehringer Ingelheim produces lay summaries of clinical trials, making complex information and data from clinical studies understandable for patients and carers.
China
Boehringer Ingelheim has been active in China since 1994. Explore career development opportunities in China or our 170 locations around the globe.
Immunology Respiratory Research
Find out more about our research and development in Immunology & Respiratory diseases
Iclepertin
Iclepertin: GlyT1 inhibitor
Algorithms to battle heartworm disease
Partnership with the University of Melbourne uses AI to develop new veterinary solutions for pets
Rabies? Not in Mexico!
Mexico has been a rabies-free country for the last five years. How does Mexico achieve this? Learn how we're collaborating in this fight against rabies.
Partnering pet therapeutics
Learn more about our research focus and our most recent partnerships regarding pet therapeutics.
The Core of our Leitbild
Who we are and what we strive for